Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 0.00 |
Average volume | -- |
---|---|
Shares outstanding | 169.71m |
Free float | 143.15m |
P/E (TTM) | -- |
Market cap | 128.98m SEK |
EPS (TTM) | -1.30 SEK |
Data delayed at least 15 minutes, as of Mar 21 2024.
More ▼
Press releases
- Immunovia has successfully acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer
- Immunovia completes analytical validation of its next-generation pancreatic cancer test
- Change in number of shares and votes in Immunovia AB (publ)
- Immunovia presents data from model development study at 2024 AACR Advances in Pancreatic Cancer medical conference
- Immunovia Publishes Interim Report for January-June 2024
- Immunovia's next-generation test to be included in large study of pancreatic cysts funded by the U.S. National Institutes of Health
- Immunovia files US patent application to protect its next-generation test
- Immunovia completes development of its pancreatic cancer detection test after substantially increasing test accuracy
- Invitation to Immunovia's Q2 presentation
- Immunovia presents data from discovery study at 2024 PancreasFest medical conference
More ▼